BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BioNexus Gene Lab Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.23+0.03 (+2.23%)
Close on Oct 19, 2026
- Market cap
- $2.97M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.5%
0M of 3M shares
Institutional holders
3
2 new, 1 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Tan Lee Su-Leng | 338,709 | 11.50% | 13D (active) | Aug 13, 2026 |
| Soo Kow Lai | 1,250,001 | 7.03% | 13D (active) | Dec 11, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BGLC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hrt Financial LP | 14,283 | 0.49% | $27 | New | 0.00% |
| UBS Group AG | 101 | 0.00% | $197 | −130 | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | 0.00% | $2 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 3 | 0M | 0.5% | 2 / 0 | 1 / 1 | 0M | 0M |
| Q1 2026 | 2 | 0M | 0.0% | 2 / 0 | 0 / 1 | 0M | 0M |
| Q4 2025 | 1 | 0M | 1.6% | 0 / 1 | 0 / 1 | 0M | 0M |
| Q3 2025 | 2 | 0M | 0.8% | 1 / 0 | 1 / 0 | 0M | 0M |
| Q2 2025 | 1 | 0M | 0.3% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BGLC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund | 2,368 | 0.08% | $5.49K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 3 | 0.00% | $6 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lee Su-Leng Tan | Chief Executive Officer, Director, 10% owner | 338,709 | 11.55% | Aug 14, 2026 |
| Set Fui Chong | Chief Financial Officer | 96,774 | 3.30% | Aug 14, 2026 |
| Jook Yuen Low | Director | 17,390 | 0.59% | Aug 14, 2026 |
| Abdul Hamid Muhammad Azrul Bin | Director | 32,258 | 1.10% | Aug 14, 2026 |
| Chee Keong Yap | Director | 32,258 | 1.10% | Aug 14, 2026 |
| Diagnostics Pte. Ltd. Fidelion | – | 392,329 | 13.37% | Aug 7, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Set Fui Chong Chief Financial Officer | Aug 13, 2026 | Award | +96,774 | – | – | 96,774 |
| Jook Yuen Low Director | Aug 13, 2026 | Award | +16,129 | – | – | 17,390 |
| Abdul Hamid Muhammad Azrul Bin Director | Aug 13, 2026 | Award | +32,258 | – | – | 32,258 |
| Lee Su-Leng Tan Chief Executive Officer, Director, 10% owner | Aug 13, 2026 | Award | +338,709 | – | – | 338,709 |
| Chee Keong Yap Director | Aug 13, 2026 | Award | +32,258 | – | – | 32,258 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.